All In Biotech

Drug Trial Radar · NCT07710612

A Phase 2 Study of ABSK043 Combined With Osimertinib

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Osimertinib in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer

Conditions

  • Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

Interventions

  • ABSK043 in combination with OsimertinibDrug

    Three potential dose levels of ABSK043 are prespecified, and Osimertinib will be administered orally at a fixed dose of 80 mg QD in escalation cohort. Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - Incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Adverse events(AEs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
  3. Serious adverse events (SAEs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
  4. Adverse events of special interest (AESIs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
  5. Progression-free survival at 12 monthTime frame: From the time patients receive the first dose of study drug to 12 months,assessed up to 5 years.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.